Evidence map›Paper›PMID 35282465›Full record

ArticleFrontiers in endocrinology2022

Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome.

Arturo Vega-Beyhart, Javier Laguna-Moreno, Daniela Díaz-Catalán, Laura Boswell, Mireia Mora, Irene Halperin, Gregori Casals, Felicia A Hanzu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Arturo Vega-BeyhartGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Javier Laguna-MorenoBiomedical Diagnostics Center, Hospital Clinic, Barcelona, Spain.
Daniela Díaz-CatalánGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Laura BoswellGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Mireia MoraGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Irene HalperinGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Gregori CasalsBiomedical Diagnostics Center, Hospital Clinic, Barcelona, Spain.
Felicia A HanzuGroup of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstituto de Salud Carlos III · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Twenty-four-hour urinary free cortisol (24h-UFC) is the most used test for follow-up decision-making in patients with Cushing syndrome (CS) under medical treatment. However, 24h-UFC determinations by immunoassays (IA) are commonly overestimated because of steroid metabolites' cross-reaction. It is still uncertain how ketoconazole (KTZ)- and metyrapone (MTP)-induced changes on the urinary steroid metabolites can alter the 24h-UFC*IA determinations' reliability. Methods: 24h-UFC was analyzed by IA and gas chromatography-mass spectrometry (GC-MS) in 193 samples (81 before treatment, 73 during KTZ, and 39 during MTP) from 34 CS patients. In addition, urinary steroidome was analyzed by GC-MS on each patient before and during treatment. Results: Before treatment, 24h-UFC*IA determinations were overestimated by a factor of 1.75 (95% CI 1.60-1.94) compared to those by GC-MS. However, during KTZ treatment, 24h-UFC*IA results were similar (0.98:1) to those by GC-MS (95% CI, 0.83-1.20). In patients taking MTP, IA bias only decreased 0.55, resulting in persistence of an overestimation factor of 1.33:1 (95% CI, 1.09-1.76). High method agreement between GC-MS and IA before treatment ( Conclusion: KTZ and MTP alter the urinary excretion of IA cross-reactive steroid metabolites, thus decreasing the cross-reactive interference of 24h-UFC*IA determinations present before treatment. Consequently, this interference reduction in 24h-UFC*IA leads to loss of method agreement with GC-MS and high risk of overestimating the biochemical impact of KTZ and MTP in controlling CS because of poor reliability of reference ranges and ULN.

Indexed as

Cushing SyndromeMetyraponeHumansHydrocortisoneImmunoassayKetoconazoleReproducibility of ResultsSteroidsHydrocortisoneKetoconazoleMetyraponeSteroidscushing syndromeimmunoassayketoconazolemass spectrometrymetyraponeurinary free cortisol

Identifiers

PMID35282465
PMCPMC8905543
OpenAlexW4212801601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.